710.3000 0.45 (0.06%)
NSE Jul 14, 2025 15:57 PM
Volume: 588.7K
 

Axis Direct
We believe KIMS has a structural growth story (strong ROCE of 32%). It is also a zero net-debt company due to its strong operating cash flow generation. Keeping this in perspective, we recommend a BUY rating on the stock with a TP of Rs 1,570/share.
Promoters unpledged 0.10% of shares in last quarter. Total pledge stands at 12.03% of promoter holdings
More from Krishna Institute of Medical Sciences Ltd.
Recommended